ArticleStem cell reviews and reports2026
A Stem Cell-Osteogenesis Axis in Malignant Breast Calcification: SQLE-Driven Reprogramming of Adipose-Derived Mesenchymal Stem Cells.
Article in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Plasma Membrane CaCancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBreast calcifications are frequent mammographic findings and serve as critical indicators for the early detection of breast cancer. Breast calcifications are formed by a mineralization process considered passive deposits resulting from tissue necrosis, but accumulating evidence suggests that calcifications may instead arise from active stromal remodeling within the tumor microenvironment. Among the diverse stromal components, mesenchymal stem cells are particularly implicated in mediating mineralization processes. Adipose-derived mesenchymal stem cells (ADSCs), abundant in breast tissue and possessing strong osteogenic potential, could therefore play a key role in mineralization process. However, their contribution of ADSCs to malignant calcification formation remains poorly understood.
methodsRNA sequencing was performed on malignant and benign calcified breast tissues to identify differentially expressed genes. Candidate genes were validated using public datasets, immunohistochemistry and survival analysis. ADSCs were isolated from patient breast tissue, phenotypically characterized and genetically modified to overexpress SQLE or HGD genes. Osteogenic differentiation was assessed by alkaline phosphatase activity, Alizarin Red S staining, qPCR and Western blot. In vivo effects were evaluated using a breast cancer xenograft model. Transcriptomic profiling, Seahorse mitochondrial stress analysis, JC-1 staining, reactive oxygen species (ROS) quantification, calcium imaging and transmission electron microscopy were used to explore the underlying mechanisms.
resultsTranscriptomic screening identified SQLE as a top upregulated gene in malignant calcifications, correlating with poor patient survival. SQLE was highly expressed in stromal cells of malignant lesions. Functional assays showed that the overexpressed SQLE markedly enhanced ADSC osteogenic differentiation and matrix mineralization, with a stronger effect than HGD. In vivo, SQLE-overexpressing ADSCs promoted ectopic calcification within tumors. Mechanistically, the overexpressed SQLE altered the ADSC transcriptome, enriched cancer- and calcium-related pathways, impaired mitochondrial oxidative phosphorylation, reduced mitochondrial membrane potential and ROS levels, and induced mitochondrial calcium accumulation with mineral deposition. The upregulation of PMCA2 and MCU mediated by overexpressed SQLE occurred prior to differentiation, followed by sustained mitochondrial calcium accumulation.
conclusionsThis study identifies SQLE as a novel driver of stromal mineralization and malignant breast calcification via mitochondrial dysfunction and calcium dysregulation. These findings challenge the passive necrosis model of calcification, positioning SQLE as both a biomarker for malignant calcifications and a potential therapeutic target for microenvironment-focused breast cancer interventions.
Indexed as
Identifiers
42014574What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.